Citations

Clear

90 citation(s) found for "Sridhar, V".

The intelligence may be artificial but the liability is real: the golden age of AI and the three hidden risks
Ramamoorti, Sridhar , Boumediene, Salem, Doty, Madison, Koritala, Bobby, Masten, Lari B., Miller, Robert, Boumediene, Salem Lotfi , Miller, Robert C.

Mayo Clinic

Journal of Information Technology Case and Application Research | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/15228053.2026.2709270 Get It

Comparative evaluation of the Mayo Clinic Florida microdosimetric kinetic model and mMKM for carbon ion treatment planning: A matRad‐based analysis
Liang, Xiaoying, Park, Chunjoo, Lu, Bo, Tan, Jun , Seckler, Lisa, Cristoforetti, Remo , Inaniwa, Taku, Beltran, Chris J., Hartzell, Shannon , Yaddanapudi, Sridhar , Furutani, Keith M. , Parisi, Alessio , Liang, Xiaoying, Lu, Bo , Inaniwa, Taku , Wahl, Niklas , Beltran, Chris

Mayo Clinic

Journal of Applied Clinical Medical Physics | June 1, 2026 | Volume: 27 | Issue: 5 | Pages: No page available

10.1002/acm2.70645 | PMID 42219622 Get It

Abstract Purpose Modeling relative biological effectiveness (RBE) is central to carbon ion radiotherapy treatment planning. The modified Microdosimetric Kinetic Model (mMKM) is a clinically established RBE framework that has guided treatment protocols at many existing carbon centers, while the Mayo Clinic Florida Microdosimetric Kinetic Model (MCF MKM) is a recently developed alternative. This work aims to implement the MCF MKM in the open‐source treatment planning system matRad and to quantitatively compare its RBE‐weighted dose predictions with those of the clinically established mMKM using identical physical dose distributions across multiple disease sites. These findings will help assess their dosimetric equivalence and inform protocol development for carbon ion radiotherapy at MCF. Methods Monte Carlo simulations of the MCF carbon beamline were performed to generate physical (IDD, LET, lateral spread) and biological base data for integration of each RBE model into matRad . Treatment plans were generated for six patients, each corresponding to a different disease site, using clinical beam configurations with carbon‐reference dose prescriptions, and plans were optimized using the MCF MKM. To isolate differences attributable solely to the RBE model, the resulting physical dose distributions were held fixed and RBE‐weighted doses were recalculated using the mMKM. Dose volume histogram (DVH) metrics and spatial dose‐difference maps were used to compare target coverage and organ‐at‐risk doses between the two models. Results Across patient cases, RBE‐weighted dose distributions from MCF MKM and mMKM showed strong agreement. Differences in target coverage were small, with CTV D95% differing by less than 1.6% across all disease sites and maximum target dose differences not exceeding 0.88%. Organ‐at‐risk dose deviations were limited, with differences of 3.0% or less across evaluated DVH metrics. Spatial dose‐difference maps showed that the largest discrepancies occurred in regions of steep dose gradients near target to organ‐at‐risk interfaces, while overall dose conformity and plan quality remained comparable between the two models. Conclusions: This study served as the first systematic model comparison of the MCF MKM and mMKM within a treatment planning environment. These findings suggest that the MCF MKM and mMKM produce dosimetrically consistent RBE‐weighted dose predictions under realistic planning conditions using carbon‐reference parameters. Accordingly, the fractionation schemes developed from years of clinical experience with mMKM implementations may serve as a practical foundation for protocol development at MCF.
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab
Galsky, Matthew D., Drakaki, Alexandra, Basu, Arnab, Bedke, Jens, Loriot, Y, Kikuchi, Eiji, Guo, J Z , Garmezy, Benjamin, Sridhar, Srikala S., Klauss, G., Lin, Daisy, Liu, Chelsea, Powles, Thomas, Galsky, Matthew D. , Drakaki, Alexandra , McGregor, Bradley A. , Bedke, Jens , Loriot, Yohann , Sridhar, Srikala S , Liu, Chelsea, Apolo, Andrea B , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps4642 Get It

TPS4642 Background: Although first-line (1L) EV + pembrolizumab has improved outcomes for patients with la/mUC, most experience disease progression, highlighting an unmet need for novel therapies. TROP2 is a glycoprotein highly expressed in several epithelial tumors, including UC. Dato-DXd is a TROP2-directed antibody–drug conjugate comprising an anti-TROP2 monoclonal antibody, a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload (DXd), designed to induce selective tumor-cell death and reduce systemic exposure to the payload. Dato-DXd has demonstrated durable efficacy and a manageable safety profile in patients with la/mUC both as monotherapy (TROPION-PanTumor01 [NCT03401385]) and in combination with immunotherapy (TROPION-PanTumor03 [NCT05489211]). We describe a Phase 2/3 trial comparing the efficacy and safety of Dato-DXd + platinum CT (carboplatin or cisplatin) vs gemcitabine + platinum CT in participants with la/mUC with disease progression on or after EV + pembrolizumab. Methods: TROPION-Urothelial03 (NCT07129993) is a global, multicenter, randomized, open-label, Phase 2/3 trial. In Part A (Phase 2), ~60 participants will be randomized 1:1 to receive Dato-DXd 4 or 6 mg/kg + platinum CT. In Part B (Phase 3), ~570 participants will be randomized 1:1 to receive Dato-DXd at the recommended Phase 3 dose (determined using Part A data) + platinum CT vs gemcitabine + platinum CT. Randomization in Part A is stratified by assignment of platinum CT (carboplatin vs cisplatin), and in Part B, by assignment of platinum CT, presence vs absence of liver metastasis at screening, and time to progression on 1L EV + pembrolizumab (<6 vs ≥6 months). Study treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, death, loss to follow-up, or other reasons per protocol. Radiographic tumor assessments occur every 6 weeks for 54 weeks, then every 12 weeks. The primary endpoint of Part A is objective response rate (ORR) by investigator per Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1). The dual primary endpoints of Part B are progression-free survival (PFS) by blinded independent central review (BICR) per RECIST 1.1 and overall survival (OS). Secondary endpoints include duration of response by investigator per RECIST 1.1 (Part A), and PFS by investigator per RECIST 1.1 and ORR by BICR and investigator per RECIST 1.1 (Part B). In Part A, ORR will be summarized with 2-sided 95% exact confidence intervals using the Clopper–Pearson method by trial group. In Part B, PFS and OS will be compared between trial groups using a log-rank test stratified by randomization stratification factors, with hazard ratios from the stratified Cox regression model. Clinical trial information: NCT07129993 .
OncoSphere AI: An agentic AI multidisciplinary clinical workflow support tool.
Desai, Aakash, McNeeley, Ellen , Alhushki, Sanad , Basu, Arnab, Thawani, Rajat, Hornstein, Nicholas J. , Elkhanany, Ahmed, Pillay, Rubin, Bodduluri, Sandeep, Thawani, Rajat , Sridhar, Arthi , Jatwani, Karan , Grewal, Udhayvir Singh , Roy, Arya Mariam , Elkhanany, Ahmed, Bodduluri, Sandeep

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e13656 Get It

e13656 Background: Effective multidisciplinary cancer care is bottlenecked by the cognitive burden of synthesizing fragmented electronic health records across different specialties. Current AI tools often function as isolated chatbots rather than integrated workflow assistants. We developed and validated "OncoSphere AI," an Agentic AI multidisciplinary clinical workflow support tool designed to autonomously orchestrate the multidisciplinary review process by deconstructing complex cases into domain-specific insights. Methods: OncoSphere AI is a novel, multi-agent large language model–driven platform that simulates a multidisciplinary tumor board for cancer care. The architecture uses a parallel reasoning framework in which eight virtual specialty agents—Medical Oncology, Radiation Oncology, Surgical Oncology, Pathology, Radiology, Pharmacy, Clinical Research, and Nurse Navigation—independently analyze structured and unstructured patient data against specialty specific guidelines and contemporary peer-reviewed literature. System performance was assessed via built-in telemetry (task completion, latency, inter-agent agreement) and blinded review by eight expert oncologists using a structured survey to rate data extraction fidelity, guideline concordance, safety, and clinical utility compared with standard manual review. Results: The study cohort (n=20, median age 59.5 years; 55% female) had a median of 2.5 (range 0-7) prior lines of therapy and multiorgan metastatic disease (median: 2, range 1–4), including lung, breast, gastrointestinal (CRC, pancreatic, hepatobiliary), and genitourinary (prostate, renal) malignancies. OncoSphere AI demonstrated high workflow utility (mean rating: 4/5) and strong extraction fidelity, with more than 90% of biomarker extractions rated as a “perfect match” by expert reviewers. Operational efficiency gains were substantial with AI processing averaged 4.7 minutes per case versus 29.3 minutes for manual review, corresponding to an 84% reduction in time (p<0.001). System telemetry revealed adaptive compute behavior, with the platform autonomously allocating 1.73-fold more reasoning tokens to complex, refractory cases than to standard scenarios. Safety review identified only one critical contraindication issue in a heavily pretreated, multi-line setting. Conclusions: OncoSphere AI effectively automates the clinical “perception layer,” consistently transforming heterogeneous longitudinal data into decision-grade insights with high fidelity and marked time savings. By operating as a coordinated ensemble of domain-specialized AI agents rather than a single generic model, it offers a scalable approach to reduce physician cognitive burden and to standardize guideline-concordant care planning in diverse, heavily pretreated oncology populations.
Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in BRCA -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
Sridhar, Srikala S., Fizazi, Karim Olivier, Chowdhury, Simon, Ryan, Charles J. , Alonso-Gordoa, Teresa, Arranz, José Ángel, Birtle, Alison , Byard, Ian, Carrozza, Francesco , Giorgi, Ugo De, Duran, Ignacio, Goeminne, Jean-charles, Goldfischer, Evan R., Despain, Darrin, Craib, Marcia, Lindberg, Henriette , Sridhar, Srikala S , Fizazi, Karim , Bryce, Alan H. , Chowdhury, Simon, Alonso‐Gordoa, Teresa , Giorgi, Ugo De , Durán, Ignacio , Goeminne, Jean‐Charles, Goldfischer, Evan R., Grimm, Marc‐Oliver , Despain, Darrin , Craib, Marcia L.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 5054-5054

10.1200/jco.2026.44.16_suppl.5054 Get It

5054 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) versus physician’s choice of docetaxel or an androgen-receptor pathway inhibitor (ARPI) (abiraterone or enzalutamide) in men with BRCA mutations who were chemotherapy-naïve in the mCRPC setting and had received one prior ARPI in the phase 3 TRITON3 trial (NCT02975934). This post-hoc analysis evaluated whether the timing of prior ARPI therapy impacted the efficacy of rucaparib. Methods: Patients were randomized 2:1 to rucaparib (600 mg BID) or physician’s choice of docetaxel or ARPI, after progression on 1 prior second-generation ARPI in any setting. The primary endpoint was rPFS. Outcomes were analyzed according to whether patients received the prior ARPI in the metastatic castration sensitive (mCSPC) or castration resistant (mCRPC) setting. Data cutoff was August 25, 2022. Results: Of the 302 BRCA1/2 patients, 68 received prior ARPI in the mCSPC setting (42 rucaparib; 26 physician’s choice) and 234 in the mCRPC setting (159 rucaparib; 75 physician’s choice). Baseline characteristics were generally similar. Prior treatments in the mCSPC and mCRPC groups, respectively, included abiraterone (73.5% vs 53.0%), enzalutamide (29.4% vs 48.3%), and docetaxel (17.6% vs 24.8%). Median rPFS favored rucaparib over physician’s choice in both groups (mCSPC: 13.6 vs 8.2 months; HR 0.60 [95% CI, 0.32–1.15]; mCRPC: 11.2 vs 5.8 months; HR 0.43 [95% CI, 0.30–0.61]). Median OS was similar between treatments in both settings (mCSPC: 23.2 vs 21.7 months; HR 0.81 [95% CI, 0.47–1.41]; mCRPC: 23.2 vs 21.0 months; HR 0.91 [95% CI, 0.66–1.25]). Treatment-related adverse events occurred at comparable rates (89.6% vs 86.1%). Conclusions: Rucaparib demonstrated efficacy in patients with BRCA-mutated mCRPC, regardless of whether prior ARPI was administered in the mCSPC or mCRPC setting. Clinical trial information: NCT02975934 .
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).
Gupta, S, Sridhar, Srikala S., Chen, Ronald C., Chan, Timothy An-thy, Wen, Yujia , Berg, S., Yen, Aihua Edward, Baghaie, Shiva, Singh, Parminder, Reimers, Melissa A., Morris, M J, Galsky, Matthew D., Rosenberg, Jonathan E., Gupta, Shilpa , Ballman, Karla V. , Apolo, Andrea B , Sridhar, Srikala S , Chan, Timothy An-thy, Singh, Parminder Pal , Reimers, Melissa A. , Morris, Michael J. , Rosenberg, Jonathan E

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4514-4514

10.1200/jco.2026.44.16_suppl.4514 Get It

4514 Background: Maintenance avelumab is a standard of care in patients (pts) with la/mUC who do not progress after first-line PBC. Cabozantinib (CABO) is an oral inhibitor of MET, VEGFR and TAM, active in multiple solid tumors. We hypothesized that an avelumab (Av)-CABO combination would improve outcomes in pts with mUC with an acceptable safety profile compared to avelumab maintenance alone. Methods: MAIN-CAV (NCT05092958) is a phase III randomized, multicenter, international trial for la/mUC pts who did not progress after 4-6 cycles of any PBC (gemcitabine-cisplatin, gemcitabine-carboplatin, MVAC, ddMVAC). Pts were randomized 1:1 to Av 800 mg IV every 2 weeks alone or with CABO 40 mg daily for ≤2 years. Stratification factors were response to first-line PBC (complete response [CR] vs partial response [PR] vs stable disease [SD]) and visceral metastases. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), safety and quality of life. The target accrual was 654 pts; the trial closed early after enrollment of 68 pts following adoption of enfortumab vedotin plus pembrolizumab as the new preferred first-line standard in the US. Results: From 3/2022 to 3/2024, 68 pts were randomized (Av n = 33; CABO-Av n = 35). Median OS was 24.8 months (mo) with Av and 23.0 mo with Avb-CABO (Hazard ratio 1.41; 95% CI 0.66–3.01; p = 0.186). Median PFS was 4.6 mo with Av vs 6.0 mo with Av-CABO (p = 0.343). Objective response rate among pts with PR or SD after first-line PBC was 20.8% with Av vs 11.5% with Av-CABO (p = 0.424). Grade ≥3 treatment-related adverse events occurred in 24.2% pts on the Av arm vs 39.4% of pts on the Av-CABO arm and CABO dose reductions occurred in 63% of pts. Conclusions: Addition of CABO to Av did not improve OS or PFS compared with Av alone in this underpowered, prematurely closed phase III trial; safety was consistent with known profiles. U10CA180821,U10CA180882; U24CA196171, U10CA180863. (CCTG);U10CA180888 (SWOG); https://acknowledgments.alliancefound.org. Clinical trial information: NCT05092958 .
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Single Ventricle: Radiology Primer for Preprocedural Evaluation
Ojha, Vineeta , Sridhar, Shravan , Moore, Alastair , Ansari‐Gilani, Kianoush , Rajiah, Prabhakar , Ojha, Vineeta , Sridhar, Shravan , Moore, Alastair , Ansari Gilani, Kianoush , Ashwath, Ravi , Rajiah, Prabhakar , Ashwath, Ravi

Mayo Clinic

RadioGraphics | March 26, 2026 | Volume: 46 | Issue: 4 | Pages: No page available

10.1148/rg.250070 | PMID 41886301 Get It

Single ventricle is a rare congenital heart defect involving one functional ventricle, and imaging is essential for classification, functional assessment, anomaly detection, and guiding management.